Misonix Primed For Stable Growth

image002

Misonix, Inc’s (NASDAQ: MSON) CEO Stavros Vizirgianakis took time to update Wall Street Analyzer’s investment audience about the company’s recent developments. During the interview he discussed MSON’s Q3 results, which produced record revenues, and also outlined their partnership with Weigao in China. Mr. Vizirgianakis also provided an overview of Misonix Inc’s key products, SonicOne and BoneScalpel, and addressed how they position them in the wound care and spine surgery sectors. He also went over MSON’s goal of transitioning most of their business to the consumables space, and how that will make their revenues even more stable and predictable.

 

CLICK HERE FOR FULL INTERVIEW

 

About Misonix:

Misonix, Inc. (NASDAQ: MSON) specializes in the development and commercialization of ultrasonic surgical devices for neurosurgical, spinal, advanced wound care, and general surgery procedures. Their portfolio of products are all based upon the unique properties of ultrasound and its ability to differentiate hard and soft tissue for different clinical requirements. Misonix, Inc. operates in over 45 countries and is a recognized leader in advanced surgical tools offering unprecedented safety, speed, and precision.

 

Company Contact:

Joe Dwyer Misonix, Inc.
631-927-9113
invest@misonix.com
www.misonix.com

 

Investor Contacts:

Robert Blum, Joe Dorame, Joe Diaz
Lytham Partners, LLC
602-889-9700
mson@lythampartners.com
www.lythampartners.com

 

About The Wall Street Analyzer 1608 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.